Back to search results

A Study of Solbinsiran for Severe Hypertriglyceridemia

This study is testing a drug called solbinsiran to see if it can safely and effectively lower very high triglyceride levels (a type of fat in the blood) in people with severe hypertriglyceridemia. You might be able to join if you are 18 or older and have a history of very high triglyceride levels (500 milligrams per deciliter or higher). To be eligible, your triglyceride levels will be checked at two separate visits during screening. The main goal is to see how much solbinsiran changes triglyceride levels compared to a placebo (an inactive substance) over 16 to 24 weeks. The study is currently recruiting about 60 participants, but its status is unclear.

Study design
This is an interventional study comparing solbinsiran to a placebo. It plans to enroll 60 participants.
What's involved
Participants will receive two injections under the skin. The study measures changes in triglycerides at baseline and between weeks 16-24.
Compensation
Not stated in the trial record.
Follow-up
Triglyceride levels will be measured at baseline and between weeks 16-24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07269210

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

Recruiting
PHASE2Ages 18+InterventionalTreatment
Eli Lilly and Company
~60 participants
Updated 2026-08-24 on ClinicalTrials.gov
What's tested:SolbinsiranPlacebo

At a glance

Recruiting sites
37 of 41 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Triglycerides
Measured over Baseline, Weeks 16-24 (Time-Average)

Conditions

Severe Hypertriglyceridemia

Explore related trials

Hypertriglyceridemia

Where it's being run

41 sites across 18 states
China6
California4
Florida4
Texas4
Virginia3
Canada3
Japan3
Arizona2

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of fasting triglyceride levels of ≥500 milligrams per deciliter (mg/dL), based on medical history
Fasting triglyceride level ≥500 mg/dL at two separate visits during screening (at least 7 days apart)
Have a body mass index (BMI) within the range of 18.5 to 45.0 kilograms per square meter (kg/m2) (inclusive)

Exclusion

Have had a major atherosclerotic cardiovascular event within the past 3 months prior to screening
Have a known genetically confirmed diagnosis of Familial Chylomicronemia Syndrome
Have a history of or planned treatment involving any gene editing or gene therapy modalities, including but not limited to CRISPR-based, viral vector-mediated, or other genetic modification techniques
Have a history of chronic alcohol abuse within 3 years prior to screening

What this trial measures

  • Change from Baseline in TriglyceridesBaseline, Weeks 16-24 (Time-Average)